Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG

Subhrajit Saha, Payel Bhanja, Ari Partanen, Wei Zhang, Laibin Liu, Wolfgang A. Tome, Chandan Guha

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The hypoxic tumor microenvironment generates oxidative Endoplasmic Reticulum (ER) stress, resulting in protein misfolding and unfolded protein response (UPR). UPR induces several molecular chaperones including heat-shock protein 90 (HSP90), which corrects protein misfolding and improves survival of cancer cells and resistance to tumoricidal therapy although prolonged activation of UPR induces cell death. The HSP90 inhibitor, 17AAG, has shown promise against various solid tumors, including prostate cancer (PC). However, therapeutic doses of 17AAG elicit systemic toxicity. In this manuscript, we describe a new paradigm where the combination therapy of a non-ablative and non-invasive low energy focused ultrasound (LOFU) and a non-toxic, low dose 17AAG causes synthetic lethality and significant tumoricidal effects in mouse and human PC xenografts. LOFU induces ER stress and UPR in tumor cells without inducing cell death. Treatment with a non-toxic dose of 17AAG further increased ER stress in LOFU treated PC and switched UPR from a cytoprotective to an apoptotic response in tumors resulting in significant induction of apoptosis and tumor growth retardation. These observations suggest that LOFU-induced ER stress makes the ultrasound-treated tumors more susceptible to chemotherapeutic agents, such as 17AAG. Thus, a novel therapy of LOFU-induced chemosensitization may be designed for locally advanced and recurrent tumors.

Original languageEnglish (US)
Pages (from-to)434-445
Number of pages12
JournalOncoscience
Volume1
Issue number6
DOIs
StatePublished - 2014

Fingerprint

tanespimycin
Unfolded Protein Response
Prostatic Neoplasms
Endoplasmic Reticulum Stress
Neoplasms
HSP90 Heat-Shock Proteins
Cell Death
Protein Unfolding
Molecular Chaperones
Tumor Microenvironment
Therapeutics
Heat-Shock Proteins
Heterografts
Cell Survival

Keywords

  • 17AAG
  • ER stress
  • Focused Ultrasound
  • Prostate Cancer
  • UPR

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG. / Saha, Subhrajit; Bhanja, Payel; Partanen, Ari; Zhang, Wei; Liu, Laibin; Tome, Wolfgang A.; Guha, Chandan.

In: Oncoscience, Vol. 1, No. 6, 2014, p. 434-445.

Research output: Contribution to journalArticle

Saha, Subhrajit ; Bhanja, Payel ; Partanen, Ari ; Zhang, Wei ; Liu, Laibin ; Tome, Wolfgang A. ; Guha, Chandan. / Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG. In: Oncoscience. 2014 ; Vol. 1, No. 6. pp. 434-445.
@article{8f0beaa2d9dc49ef9f7c796358483003,
title = "Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG",
abstract = "The hypoxic tumor microenvironment generates oxidative Endoplasmic Reticulum (ER) stress, resulting in protein misfolding and unfolded protein response (UPR). UPR induces several molecular chaperones including heat-shock protein 90 (HSP90), which corrects protein misfolding and improves survival of cancer cells and resistance to tumoricidal therapy although prolonged activation of UPR induces cell death. The HSP90 inhibitor, 17AAG, has shown promise against various solid tumors, including prostate cancer (PC). However, therapeutic doses of 17AAG elicit systemic toxicity. In this manuscript, we describe a new paradigm where the combination therapy of a non-ablative and non-invasive low energy focused ultrasound (LOFU) and a non-toxic, low dose 17AAG causes synthetic lethality and significant tumoricidal effects in mouse and human PC xenografts. LOFU induces ER stress and UPR in tumor cells without inducing cell death. Treatment with a non-toxic dose of 17AAG further increased ER stress in LOFU treated PC and switched UPR from a cytoprotective to an apoptotic response in tumors resulting in significant induction of apoptosis and tumor growth retardation. These observations suggest that LOFU-induced ER stress makes the ultrasound-treated tumors more susceptible to chemotherapeutic agents, such as 17AAG. Thus, a novel therapy of LOFU-induced chemosensitization may be designed for locally advanced and recurrent tumors.",
keywords = "17AAG, ER stress, Focused Ultrasound, Prostate Cancer, UPR",
author = "Subhrajit Saha and Payel Bhanja and Ari Partanen and Wei Zhang and Laibin Liu and Tome, {Wolfgang A.} and Chandan Guha",
year = "2014",
doi = "10.18632/oncoscience.48",
language = "English (US)",
volume = "1",
pages = "434--445",
journal = "Oncoscience",
issn = "2331-4737",
publisher = "Impact Journals",
number = "6",

}

TY - JOUR

T1 - Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG

AU - Saha, Subhrajit

AU - Bhanja, Payel

AU - Partanen, Ari

AU - Zhang, Wei

AU - Liu, Laibin

AU - Tome, Wolfgang A.

AU - Guha, Chandan

PY - 2014

Y1 - 2014

N2 - The hypoxic tumor microenvironment generates oxidative Endoplasmic Reticulum (ER) stress, resulting in protein misfolding and unfolded protein response (UPR). UPR induces several molecular chaperones including heat-shock protein 90 (HSP90), which corrects protein misfolding and improves survival of cancer cells and resistance to tumoricidal therapy although prolonged activation of UPR induces cell death. The HSP90 inhibitor, 17AAG, has shown promise against various solid tumors, including prostate cancer (PC). However, therapeutic doses of 17AAG elicit systemic toxicity. In this manuscript, we describe a new paradigm where the combination therapy of a non-ablative and non-invasive low energy focused ultrasound (LOFU) and a non-toxic, low dose 17AAG causes synthetic lethality and significant tumoricidal effects in mouse and human PC xenografts. LOFU induces ER stress and UPR in tumor cells without inducing cell death. Treatment with a non-toxic dose of 17AAG further increased ER stress in LOFU treated PC and switched UPR from a cytoprotective to an apoptotic response in tumors resulting in significant induction of apoptosis and tumor growth retardation. These observations suggest that LOFU-induced ER stress makes the ultrasound-treated tumors more susceptible to chemotherapeutic agents, such as 17AAG. Thus, a novel therapy of LOFU-induced chemosensitization may be designed for locally advanced and recurrent tumors.

AB - The hypoxic tumor microenvironment generates oxidative Endoplasmic Reticulum (ER) stress, resulting in protein misfolding and unfolded protein response (UPR). UPR induces several molecular chaperones including heat-shock protein 90 (HSP90), which corrects protein misfolding and improves survival of cancer cells and resistance to tumoricidal therapy although prolonged activation of UPR induces cell death. The HSP90 inhibitor, 17AAG, has shown promise against various solid tumors, including prostate cancer (PC). However, therapeutic doses of 17AAG elicit systemic toxicity. In this manuscript, we describe a new paradigm where the combination therapy of a non-ablative and non-invasive low energy focused ultrasound (LOFU) and a non-toxic, low dose 17AAG causes synthetic lethality and significant tumoricidal effects in mouse and human PC xenografts. LOFU induces ER stress and UPR in tumor cells without inducing cell death. Treatment with a non-toxic dose of 17AAG further increased ER stress in LOFU treated PC and switched UPR from a cytoprotective to an apoptotic response in tumors resulting in significant induction of apoptosis and tumor growth retardation. These observations suggest that LOFU-induced ER stress makes the ultrasound-treated tumors more susceptible to chemotherapeutic agents, such as 17AAG. Thus, a novel therapy of LOFU-induced chemosensitization may be designed for locally advanced and recurrent tumors.

KW - 17AAG

KW - ER stress

KW - Focused Ultrasound

KW - Prostate Cancer

KW - UPR

UR - http://www.scopus.com/inward/record.url?scp=84940053308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940053308&partnerID=8YFLogxK

U2 - 10.18632/oncoscience.48

DO - 10.18632/oncoscience.48

M3 - Article

AN - SCOPUS:84940053308

VL - 1

SP - 434

EP - 445

JO - Oncoscience

JF - Oncoscience

SN - 2331-4737

IS - 6

ER -